niclosamide has been researched along with Insulin Resistance in 3 studies
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Niclosamide piperazine salt may hold the promise to become an alternative to NEN as a drug lead for the treatment of obesity and T2D." | 7.91 | Niclosamide piperazine prevents high-fat diet-induced obesity and diabetic symptoms in mice. ( Alasadi, A; Guo, J; Huang, Q; Jin, S; Tao, H, 2019) |
| "To assess the anti-obesity effects of niclosamide on mice with induced obesity." | 7.85 | Niclosamide as an anti-obesity drug: an experimental study. ( Al-Gareeb, AI; Aljubory, KD; Alkuraishy, HM, 2017) |
| "Niclosamide piperazine salt may hold the promise to become an alternative to NEN as a drug lead for the treatment of obesity and T2D." | 3.91 | Niclosamide piperazine prevents high-fat diet-induced obesity and diabetic symptoms in mice. ( Alasadi, A; Guo, J; Huang, Q; Jin, S; Tao, H, 2019) |
| "To assess the anti-obesity effects of niclosamide on mice with induced obesity." | 3.85 | Niclosamide as an anti-obesity drug: an experimental study. ( Al-Gareeb, AI; Aljubory, KD; Alkuraishy, HM, 2017) |
| "Niclosamide is an anthelmintic drug approved by the US Food and Drug Administration that uncouples the mitochondria of parasitic worms." | 1.40 | Niclosamide ethanolamine-induced mild mitochondrial uncoupling improves diabetic symptoms in mice. ( Jin, S; Shulman, GI; Tao, H; Zeng, X; Zhang, Y, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, J | 1 |
| Tao, H | 2 |
| Alasadi, A | 1 |
| Huang, Q | 1 |
| Jin, S | 2 |
| Zhang, Y | 1 |
| Zeng, X | 1 |
| Shulman, GI | 1 |
| Al-Gareeb, AI | 1 |
| Aljubory, KD | 1 |
| Alkuraishy, HM | 1 |
3 other studies available for niclosamide and Insulin Resistance
| Article | Year |
|---|---|
Niclosamide piperazine prevents high-fat diet-induced obesity and diabetic symptoms in mice.
Topics: Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Insulin Resistance; Mice | 2019 |
Niclosamide ethanolamine-induced mild mitochondrial uncoupling improves diabetic symptoms in mice.
Topics: Administration, Oral; Animals; Blood Glucose; Cell Respiration; Diabetes Mellitus, Experimental; Die | 2014 |
Niclosamide as an anti-obesity drug: an experimental study.
Topics: Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Cholesterol; Diet, High-Fat; Eating; Insul | 2017 |